Adipose tissue secretory proteins, called adipokines, play pivotal roles in the pathophysiology of obesity and its associated disorders such as metabolic syndrome, type 2 diabetes, and cardiovascular disease. Because methods for comprehensive adipokine profiling in patient plasma and other biological samples are currently limited, we developed a multiplex immunoassay for rapid and high-throughput measurement of 25 adipokines in only 50 L of sample.
Adipose tissue, with its secretory proteins called "adipocytokines" or "adipokines," has over the last decade emerged as an important endocrine organ (1, 2 ) . Expansion of adipose tissue, as seen in obese individuals, results in qualitative and quantitative changes in a number of adipokines (2, 3 ) . The implications vary because of differences in mode of action; adiponectin regulates hepatic glucose metabolism and has antiinflammatory effects on the vascular wall (4 ), whereas leptin exhibits systemic effects on appetite and metabolism (3 ) , and the novel adipokines chemerin and cathepsin S affect adipogenesis and atherosclerotic plaque growth and destabilization, respectively (5) (6) (7) . The adipokine profile changes induce local and systemic low-grade inflammation, which contributes to obesity-associated pathologies such as metabolic syndrome, type 2 diabetes, and cardiovascular disease (3, 8 ) . In light of the search for cardiovascular biomarkers that augment information obtained from clinical parameters and illuminate disease mechanisms, adipokines are considered promising candidates (9, 10 ) .
Although robust and high-throughput methods for adipokine profiling could strongly fuel research into obesity and its associated disorders, comprehensive adipokine profiling remains difficult. ELISAs are widely used for their user-friendliness, low detection limits, and robustness compared with other antibodybased and mass spectrometry techniques (11 ) ; however, they have difficulty with adipokine diversity because they measure 1 adipokine at a time. Bead-based multiplex immunoassays (MIAs) 6 share the sandwich ELISA principle and are characterized by similar userfriendliness and robustness (12) (13) (14) . In addition, MIAs render superior binding kinetics and limits of quanti-fication compared with solid-carrier immunoassays like ELISA because the antibody-coated microspheres are suspended in the analyte sample during the assay. More importantly, the use of carboxylated microspheres with distinct fluorescent labels enables simultaneous measurement of many proteins. For these reasons, MIA has established itself as an excellent profiling tool (12) (13) (14) .
Here we report the development of the first comprehensive human adipokine MIA, enabling measurement of 25 adipokines in only 50 L of sample. To show its usefulness in biological samples, we furthermore present adipokine profiling of (pre)adipocyte supernatants, ex vivo cultured adipose tissue, and human plasma samples.
Materials and Methods

PATIENT SAMPLES
We obtained fasting patient heparinized blood samples during the daytime, with informed consent and permission of the local medical ethics committee (protocol number 09-210). We recruited healthy age-and sex-matched normal weight controls from laboratory personnel. All heparinized blood samples were centrifuged 400g for 10 min, after which the plasma was aliquoted and stored at Ϫ80°C until analysis. Before analysis, all plasma samples were centrifuged on a 0.22-m nylon membrane (Spin-X column, Corning) to remove cellular debris. To prevent interference from heterophilic antibodies, we removed immunoglobulins by 1-h incubation on protein L-coated plates (Pierce) (15 ) .
Subcutaneous abdominal adipose tissue was residual material from a 38-year-old woman undergoing abdominoplastic surgery. Fifty grams of the adipose tissue was washed twice with PBS, cut in pieces of approximately 5 by 5 by 5 mm, and incubated for 24 h on a shaker in 25 mL DMEM/F12 (Dulbecco) containing 1% penicillin/streptomycin (Invitrogen) and 20 nM insulin (Sigma). The supernatant was aliquoted and stored at Ϫ80°C.
CELL AND TISSUE CULTURE
Culturing and differentiation of the human SimpsonGolabi Behmel syndrome (SGBS) preadipocyte cell line was performed as described (16, 17 ) . On day 8 of differentiation, medium was conditioned for 24 h, aliquoted, and stored at Ϫ80°C. We assessed differentiation by oil-red-O staining, as described (18 ) .
CONJUGATION OF ANTIBODIES TO MICROSPHERES
Carboxylated polystyrene microspheres (xMAP, Luminex) were covalently conjugated to commercially available capture antibodies, as described (19 ) .
We performed all conjugations with 25 g capture antibody dissolved in 250 L PBS and 2.5 ϫ 10 6 beads, except for retinol binding protein 4 (RBP-4), which required 100 g antibody for optimal assay performance.
MULTIPLEX IMMUNOASSAY
Supernatants were analyzed undiluted. Plasma samples were analyzed both undiluted and 100ϫ diluted in serum diluent (R&D Systems) and PBS (1:1), the latter for measurement of plasma adipokines present in very high concentrations, i.e., adipsin, cathepsin S, leptin, adiponectin, chemerin, plasminogen activator inhibitor 1 (PAI-1), RBP-4, serum amyloid A1 (SAA-1), tissue inhibitor of metalloproteinase 1 (TIMP-1), and thrombopoietin.
All assays were carried out at room temperature and protected from light. We prepared calibration curves as 2-fold dilution series in serum diluent with PBS (1:1). Plasma samples (45 L) were preincubated with 5 L rat/mouse (1:1) serum for 5 min at room temperature for further reduction of heterophilic antibody binding. We transferred 50 L of calibrator, blank, or sample to 96-well 1.2-m filter plates (Millipore) prewetted with PBS and added a mix containing 1000 microspheres per adipokine (total volume 10 L/ well) to all wells. The plate was incubated for 1 h with continuous shaking. We then added 10 L of a cocktail of biotinylated antibodies (16.7 mg/L each) to the wells, followed by 1-h incubation. After incubation, the plate was washed and incubated for 10 min with streptavidin-PE (50 g/L, Becton Dickinson) 100ϫ diluted in high-performance ELISA (HPE) buffer (Sanquin). After washing, we measured the fluorescence intensity of the beads in a final volume of 100 L HPE buffer. All washing steps were performed with 1% BSA/ 0.05% Tween/0.001% sodium azide in PBS in an automated plate washer (Bio-Plex Pro II wash station, Bio-Rad).
Measurements and data analysis of all assays were performed on the Bioplex system in combination with Bioplex manager software version 4.1.1 by use of a 5-parametric curve fitting (Bio-Rad).
ASSAY CHARACTERISTICS
Dynamic range. The MIA adipokine dynamic ranges were defined by the concentration ranges the calibration curves covered. To optimize dynamic ranges, we titrated all MIA adipokine calibrator series (13 points) to a maximum fluorescence intensity of at least 3000.
Cross-reactivity. To determine assay cross-reactivity, we tested the response of adipokine microspheres to single recombinant adipokines. Single recombinant adipokines were dissolved in HPE buffer and tested at concentrations of 500 000 ng/L for adipokines with highest calibration point Ն500 000 ng/L, at 50 000 ng/L for adipokines with highest calibration point between 5000 and 500 000 ng/L, and at 5000 ng/L for adipokines with highest calibration point Յ5000 ng/L. We calculated percentage of cross-reactivity as the ratio of fluorescence intensity in response to a single recombinant adipokine compared with the maximum fluorescence intensity.
Assay reproducibility. To assess reproducibility of the MIA adipokine panel, we measured triplicates of 11 samples on 3 consecutive days. We assessed intraassay variation as the mean CV for the triplicates and interassay variation as the mean CV for the 3 consecutive runs.
Lower limit of detection and quantification. We assessed the lower limit of detection (LLOD) and quantification (LLOQ) for all adipokines. For all adipokines, we calculated the blank average MFI (n ϭ 26 over 3 consecutive runs), MFI standard deviation (SD), and 2*SD. Adipokine LLODs were determined by interpolation of the mean blank MFI ϩ 2*SD in the 5-parameter logistic adipokine standard curves. The LLOQ was calculated as 3*LLOD (20 ) .
ELISAs
A comparison of MIA and ELISA for most of the cytokines and chemokines in the MIA adipokine panel has been published by our group (15, 19 ) . ELISAs available for the other adipokines, i.e., adiponectin, adipsin, granulocyte-macrophage colony-stimulating factor (GM-CSF), hepatocyte growth factor (HGF), leptin, PAI-1, resistin, TIMP-1, and thrombopoietin (all R&D Systems), were performed according to the manufacturer's protocols. Absorbance of the ELISAs was read at 450 nm on an iMark microplate reader (Bio-Rad). We 
STATISTICS
We studied differences in adipokine concentrations between obese individuals and sex-and age-matched nonobese controls using paired t-tests. P values were adjusted for multiple testing using Benjamini and Hochbergs false discovery rate correction (21 ) . Pearson correlation coefficients were determined to assess correlation between the MIA and ELISA measurements. SPSS 15.0.1 (SPSS Software) and GraphPad Prism 4.02 (GraphPad Software) were used for statistical analysis.
Results
MIA DEVELOPMENT AND VALIDATION
To develop a MIA for adipokines, 25 recombinant adipokine proteins plus specific capture and detection antibody pairs (Table 1) were tested for lower limits of detection and quantification, cross-reactivity, and intra-and interassay variation. All recombinant protein-antibody combinations were optimized in single bead assays before being included in the multiplex panel.
The MIA calibration curves showed high maximum fluorescence intensities and broad dynamic ranges (Fig. 1) . The LLODs and LLOQs (Table 2) showed that the majority of adipokines could be measured in low concentration and fluorescence ranges. The supernatant and plasma concentrations of the 5 adipokines with a higher LLOQ (adiponectin, chemerin, PAI-1, SAA-1, and RBP-4, LLOQ Ͼ100 ng/L) all exceeded their LLOQ, so these adipokines could be measured reliably as well.
We assessed cross-reactivity by testing high concentrations of a given recombinant adipokine against the full panel of adipokine capture and detection antibodies. Most of the recombinant adipokine proteins did not display cross-reactivity with antibodies directed against other adipokines. Only 2 nonspecific (PAI-1 recombinant protein, RBP-4 antibody pair) and 3 specific cross-reactions (Ͼ1%) were observed (Table 3) . Resistin antibodies displayed 10.8% crossreactivity to PAI-1 recombinant protein, indicating that resistin measurements might be affected in the case of high PAI-1 concentrations. It should be noted, however, that in all other cases cross-reactions were observed at recombinant adipokine concentrations that exceed physiological concentrations, thereby reducing the chance of cross-reactivity in physiological samples.
Intraassay variation (CV%) was Ͻ10% for all adipokines, with a mean intraassay variation of 4.6%. Interassay variation was Ͻ15%, with a mean interassay variation of 7.7% ( Table 2 ). The measured intra-and interassay variations are comparable to or lower than the variations usually reported for adipokine ELISAs (22 ) .
MIA results correlated significantly with ELISA adipokine measurements of the supernatants and plasma samples (Table 2 ), but 4 categories of adipokines could be distinguished. For most of the cytokines and chemokines, ELISAs with the same antibody pairs used for the MIA were available, resulting in optimal correlations (Pearson R Ͼ 0.9, P Ͻ 0.0001), as published before (15 ) . For adiponectin, adipsin, HGF, leptin, PAI-1, resistin, TIMP-1, and thrombopoietin, the antibody pairs used for ELISA and MIA may be identical, but the antibody clones were not disclosed by the ELISA manufacturer. These adipokines showed significant but variable correlation (Pearson R between 0.59 and 0.93) between MIA and ELISA, probably due to MIA-ELISA antibody (dis)similarities. Next, for cathepsin S, chemerin, interleukin (IL)-1RA, monocyte chemoattractant protein 1 (MCP-1), M-CSF, macrophage migration inhibitory factor (MIF), nerve growth factor (NGF), RBP-4, and SAA1, ELISAs with the same antibody pairs as the MIA were not available and were not performed. Finally, GM-CSF concentrations in the supernatants and plasma samples were below ELISA limit of detection.
HUMAN ADIPOKINE PROFILING IN BIOLOGICAL SAMPLES
To investigate whether the human adipokine MIA could be applied to various biological samples, we generated adipokine profiles of preadipocyte, adipocyte, and adipose tissue supernatants together with plasma adipokine profiles of morbidly obese patients and healthy, normal-weight sex-and age-matched controls. First, supernatants were collected of human SGBS cells, either before or after differentiation into mature adipocytes (see Supplemental Fig. 1 , which accompanies the online version of this article at http:// www.clinchem.org/content/vol56/issue8). All 25 adipokines were detected in the supernatants, either before or after differentiation (Fig. 2, depicted as heat  map) . SGBS preadipocytes secreted more IL-1␤, IL-6, IL-8, MCP-1, and PAI-1 than differentiated adipocytes, whereas adipocytes secreted more adiponectin and RBP-4. When adipokine profiling was performed on supernatant of ex vivo cultured adipose tissue, several adipokines were detected that were also found to be secreted by SGBS adipocytes (Fig. 2) . In addition, high concentrations of cathepsin S, IL-6, MCP-1, and PAI-1 were found (Fig. 2) , probably reflecting the presence of preadipocytes and stromal vascular cells in the tissue sample. Finally, we performed adipokine profiling of 5 morbidly obese women and 5 sex-and agematched normal-weight controls (Table 4) . Except for GM-CSF, IL-6, macrophage inflammatory protein 1␣ (MIP-1␣), and tumor necrosis factor ␣ (TNF-␣), all adipokines could be detected in both obese patient and control plasma samples (Fig. 2) . Furthermore, morbidly obese patients showed significantly lower concentrations of adiponectin and higher concentrations of leptin and the novel adipokines cathepsin S and chemerin. When corrected for multiple testing, differences in leptin (P ϭ 0.006), cathepsin S (P ϭ 0.026), and chemerin (P ϭ 0.010) concentrations remained significant, whereas differences in adiponectin concentrations could not be established anymore (P ϭ 0.227), probably because of the small sample size.
Discussion
In this study, we report the development and validation of an MIA for comprehensive profiling of human adipokines. The assay shows advantages over adipokine ELISAs and other techniques by enabling measurement of 25 adipokines in only 50 L of sample. This large adipokine MIA adds to the smaller commercial adipokine MIA panels (up to 8 adipokines) that have a Intra-and interassay variation were calculated after measuring 11 different samples in triplicate for 3 consecutive days. LLOD and LLOQ were calculated after measuring a total of 26 blanks over 3 consecutive days. Ͻ, the LLOD and/or LLOQ could not be calculated by interpolation in the 5-parameter logistic adipokine standard curves, as they were too low to fit in the logistic curves. b The highest to lowest concentration covered by the calibration curve. c ND, not determined. ELISA kits with the same antibody pair clones as used for the MIA were either not available or were not able to detect adipokine levels in the supernatants and plasma samples (GM-CSF). d MIA and ELISA results were compared in an earlier publication of our group [de Jager et al. (15 ) The header usually has shortened names for the protein column on the left; the order for the header and the protein column is exactly the same. Cross-reactions (Ͼ1%).
been described so far (22 ) . Furthermore, the assay is characterized by low limits of quantification, crossreactivity, and intra-and interassay variation together with potential flexibility-i.e., newly discovered adipokines (e.g., visfatin) could be added to the MIA panel as soon as appropriate capture and detection antibodies become available.
There are a few general considerations for cytokine and adipokine measurements with ELISA and MIA techniques. First, long-term storage (Ͼ2 years at Ϫ80°C) and repeated freeze-thawing can influence the measurements (23 ) . Second, matrix characteristics such as protein content and pH affect protein concentrations detected (12 ) . Sample dilution thus requires standardization. We chose to measure all adipokines undiluted except for adipsin, cathepsin S, leptin, adiponectin, chemerin, PAI-1, RBP-4, SAA-1, TIMP-1, and thrombopoietin, which occur in high concentrations in human plasma. Third, to avoid interference of heterophilic antibodies, preincubation of the plasma samples on protein L-coated plates followed by a blocking step with rodent serum is needed, as described (15 ) . Finally, antibody-based assays like ELISA and MIA render semiquantitative results. Although relative sample differences can be compared, absolute concentrations vary even between ELISA kits (24, 25 ) . One of the reasons for the latter is illustrated by the MIA-ELISA correlation studies we performed. As described earlier, comparing MIA and/or ELISA assays using different antibody clones renders lower correlations (12, 13, 22, 24, 25 ) . Meaningful MIA and/or ELISA comparisons for validation purposes thus require analogous antibody clones. In our study, the MIA adipokines that, for this reason, could not be compared with ELISAs still showed good reproducibility, specificity, and limits of quantification, as required generally for new antibody-based assays like ELISA and MIA (26 ) .
The human adipokine MIA showed its value in several ways. When profiling the supernatants of human SGBS preadipocytes and adipocytes, we found that high concentrations of adiponectin were secreted by adipocytes, whereas preadipocytes secreted more IL-6, IL-8, PAI-1, and MCP-1, in agreement with previous studies (27 ) . Taking note of the fact that adipokine profiles of SGBS adipocytes and primary adipocytes might show differences, our findings do support a role for the adipokine MIA in studying the effects of bioactive compounds (e.g., lipids) on adipokine profiles in simplified model systems, such as cultured (pre)adipocytes. Furthermore, we observed interesting differences between the plasma adipokine profiles of morbidly obese patients and sex-and age-matched controls. While as a Adipokine concentrations are displayed in 2 groups. The upper panel displays adipokines present in concentrations between 1 and 100 000 ng/L, and the lower panel displays adipokines present in concentrations between 100 and 10 000 000 ng/L. For all significant differences between obese patients and controls, mean adipokine concentrations and corresponding P values are shown (paired t-tests). ND, not determinable (levels below detection limit). Human Adipokine Profiling proof of concept our data confirmed the wellestablished link between obesity and plasma leptin concentrations (3, 4 ) , our data also underlined the potential relevance of cathepsin S and chemerin in obesity and its associated disorders (7, 28 -30 ) . We therefore conclude that this novel method can be of value for both comprehensive adipokine profiling in large patient cohorts and biological discovery in cellular model systems.
